7d
Hosted on MSNOzempic Now FDA-Approved for Kidney Disease-Here's What to KnowGLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
The FLOW trial of 3,533 patients is the first primary kidney trial with an incretin mimetic, semaglutide. Like CREDENCE, FLOW was conducted in adults with type 2 diabetes. Participants were ...
Credit: Novo Nordisk. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial. Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV ...
Semaglutide, used for diabetes and obesity, may reduce alcohol cravings in adults with alcohol use disorder, offering a potential solution to a major treatment gap.
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results